Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), approved by the US Food and Drug Administration (FDA) as weight loss medications, have demonstrated significant potential in managing obesity-related renal injury. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.